- Details
- Description
Packaging Size:
As stated on the product packaging
Strength:
110 mg
Composition:
Revumenib 110 mg
Treatment:
Certain types of acute leukemia, including appropriate cases of KMT2A-rearranged acute leukemia, as prescribed by a healthcare professional.
Form:
Tablet
Brand:
LuciRevu
Quantity Unit:
Tablets
Manufacturer:
Lucius Pharma
LuciRevu 110 (Revumenib) is a prescription medicine used in the treatment of certain types of acute leukemia. It is a targeted menin inhibitor that works by blocking menin, a protein involved in abnormal gene regulation and the growth of certain leukemia cells.
LuciRevu 110 is intended for oral use and may be used for appropriate patients with specific forms of acute leukemia, including certain KMT2A-rearranged cases, according to the prescribing physician's instructions. Treatment should be carried out under appropriate medical supervision.
